“…We have studied MCP-2 and found a lower sensitivity of 71% for active TB at 97% specificity in healthy controls, but no significant added effect by combination with either IP-10 or IFN-g [52]. In a subsequent eval uation in HIV-infected patients with confirmed TB, we observed significant lower sensitivity of MCP-2 compared with IFN-g and IP-10, and found no added effect by combination Tweaking of the incubation step, for example by increasing incubation temperature [49], prolonging the incubation period [23,92,93], improving culture conditions with nutrients [201] or addition of proinflammatory cytokines (e.g., IL-12 [85]), blocking of anti-inflammatory cytokines (e.g., IL-10 [49,94]) or adding 'survival' cytokines (e.g., IL-7 [95,96]), have also shown potential for augmentation of the antigen-specific immune response.…”